Systematic Review
Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials

https://doi.org/10.1016/j.jceh.2018.05.004Get rights and content

Background/objectives

l-Ornithine l-Aspartate (LOLA) is a mixture of two endogenous amino acids with the capacity to fix ammonia in the form of urea and/or glutamine. Its’ efficacy for the treatment of Hepatic Encephalopathy (HE), a known hyperammonemic disorder, remains the subject of debate. This study quantitatively analyzed the efficacy of LOLA in patients with cirrhosis and HE.

Methods

Efficacy was defined as the extent of lowering of blood ammonia and improvement of mental state assessed in clinically overt HE (OHE) by Westhaven criteria or psychometric testing for assessment of Minimal HE (MHE). Appropriate keywords were used for electronic and/or manual searches of databases to identify RCTs for inclusion. Study quality and risk of bias were assessed using the Jadad Composite Scale together with The Cochrane Scoring Tool. Random Effects Models were used to express pooled Risk Ratio (RR) or Mean Difference (MD) with associated 95% Confidence Intervals (CI).

Results

10 RCTs (884 patients) were included. Regression analysis showed no evidence of publication bias or other small study effects. Eight RCTs had low risk of bias by Jadad/Cochrane criteria. Comparison with placebo/no intervention controls revealed that LOLA was significantly more effective for improvement of mental state in all types of HE (RR 1.36 (95% CI 1.10–1.69), p = 0.005), OHE (RR: 1.19, 95% CI of 1.01–1.39, test for overall effect: Z = 2.14, p = 0.03), MHE (RR: 2.15 (1.48–3.14), p < 0.0001) and for lowering of blood ammonia (MD: −17.50 μmol/l (−27.73 to (−7.26)), p = 0.0008). Improvement of mental state was greater in trials with low risk of bias. Heterogeneity was reduced in trials from Europe or with >100 participants. Oral LOLA appeared particularly effective for the treatment of MHE.

Conclusion

LOLA appears to improve mental state and lower ammonia in patients with HE or MHE. Further studies are required in some subgroups of HE and in the era of HE reclassification.

Section snippets

Search Criteria

This involved electronic and manual searches using appropriate keywords as follows: Search strings: (1) Hepatic Encephalopathy (HE), (2) Overt Hepatic Encephalopathy (OHE), (3) Minimal Hepatic Encephalopathy (MHE), (4) l-Ornithine l-Aspartate (LOLA), (5) Intravenous Formulation (iv), (6) oral formulation (oral), (7) cirrhosis, (8) Randomized Controlled Trial (RCT). Search string: (#1 or #2 or #3) and (#4 or #5) and #7 and #8. Medline, PubMed, the Cochrane Controlled Trials Register (2008),

Results

Electronic searches of the databases identified 43 trials with a further 16 from manual searches. Five full-text articles were excluded for reasons of incompatibility of data presentation required for pooling. Following removal of duplicate citations and elimination of published studies in line with eligibility and inclusion/exclusion criteria, a total of 10 trials were included in the final meta-analysis (Figure 1) where sufficient data were available for pooling. Included trials are

Discussion

Hyperammonemia: Results of the present systematic review and meta-analysis significantly extend the findings of a number of individual RCTs namely that LOLA is effective in lowering blood ammonia in patients with cirrhosis. Pooled data from the eight RCTs in which blood ammonia was measured in all patients with HE revealed that blood ammonia was significantly reduced although the degree of reduction was variable from trial-to-trial, the overall effect was statistically significant (MD: −17.50,

Conflicts of Interest

The authors have none to declare.

References (39)

  • R.K. Dhiman et al.

    Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy

    Dig Dis Sci

    (2000)
  • N.M. Bass et al.

    Rifaximin treatment in hepatic encephalopathy

    N Engl J Med

    (2010)
  • C. Rose et al.

    l-Ornithine l-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action

    Metab Brain Dis

    (1998)
  • S. Rathi et al.

    Managing encephalopathy in the outpatient setting

    Clin Liver Dis

    (2016)
  • G. Kircheis

    Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of l-ornithine-l-aspartate in the management of HE

    Metab Brain Dis

    (2016)
  • A.M. Delcker et al.

    l-Ornithine l-aspartate versus placebo in the treatment of hepatic encephalopathy: a meta-analysis of randomised placebo-controlled trials using individual data

    Hepatology

    (2000)
  • Q. Jiang et al.

    l-Ornithine l-aspartate in the management of hepatic encephalopathy: a meta-analysis

    J Gastroenterol Hepatol

    (2009)
  • M. Bai et al.

    l-Ornithine l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials

    J Gastroenterol Hepatol

    (2013)
  • S.S. Sidhu et al.

    l-Ornithine l-aspartate in bouts of overt hepatic encephalopathy

    Hepatology

    (2018)
  • Cited by (47)

    • Establishment of hyperammonemia mode in yellow catfish and the mitigation of exogenous L-ornithine-L-aspartate

      2022, Developmental and Comparative Immunology
      Citation Excerpt :

      It has been shown to reduce blood ammonia levels in mammal experiment with hyperammonemia (Rose et al., 1999). Several mechanisms have been proposed to explain the effect of LoLa on hyperammonemia: 1) participates in ammonia metabolism via l-ornithine and/or l-aspartate and related metabolites including glutamate, glutamine and glutathione; 2) increases nitric oxide synthesis by increasing arginine production; 3) increases glutathione synthesis from glutamate and reduces harmful reactive species contents, thereby enhancing antioxidant capacity; 4) reduces the occurrence of hepatocyte necrosis and apoptosis (Butterworth and Gruengreiff, 2018; Butterworth et al., 2018; Sidhu, 2018). In aquaculture, LoLa has potential value in treating ammonia poisoning in fish due to its low price.

    • Nutraceuticals for the treatment of sarcopenia in chronic liver disease

      2021, Clinical Nutrition ESPEN
      Citation Excerpt :

      Therefore, LOLA enhances ammonia clearance through these dual pathways [71]. In clinical trials, LOLA improves both overt and minimal hepatic encephalopathy [72]. Furthermore, the metabolites of LOLA including glutamine, l-arginine and glutathione have potent antioxidant properties and improve hepatic microcirculation which may have additional hepatoprotective effects [73].

    • Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy

      2020, Journal of Hepatology
      Citation Excerpt :

      The efficacy of oral LOLA has been a subject of debate, as the AASLD-EASL clinical guidelines suggested that oral supplementation with LOLA is not effective.1 Recent meta-analyses204–206 suggest that LOLA has beneficial effects on HE, decompensation, and mortality, but the number of clinical trials analysed was dissimilar in the reports, with one stating that the quality of evidence was very low.206 Thus, the potential beneficial effect of LOLA remain uncertain.

    View all citing articles on Scopus
    View full text